Safety and immunogenicity of a SARS-CoV-2 Gamma variant RBD-based protein adjuvanted vaccine used as booster in healthy adults.
Pasquevich KA, Coria LM, Ceballos A, Mazzitelli B, Rodriguez JM, Demaría A, Pueblas Castro C, Bruno L, Saposnik L, Salvatori M, Varese A, González S, González Martínez VV, Geffner J, Álvarez D; Laboratorio Pablo Cassará R&D and CMC for ARVAC CG consortium; Feleder E, Halabe K, Perez Lera PE, de Oca FM, Vega JC, Lombardo M, Yerino GA, Fló J, Cassataro J.
Pasquevich KA, et al. Among authors: gonzalez martinez vv, gonzalez s.
Nat Commun. 2023 Jul 28;14(1):4551. doi: 10.1038/s41467-023-40272-3.
Nat Commun. 2023.
PMID: 37507392
Free PMC article.
Clinical Trial.